Pyxis Oncology, Inc. (PYXS) vs Atrium Therapeutics, Inc. (RNA)
A side-by-side comparison of Pyxis Oncology, Inc. and Atrium Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PYXS
Pyxis Oncology, Inc.
$2.05HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
RNA
Atrium Therapeutics, Inc.
$7.97HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
Total return — PYXS vs RNA
growth of $100 · dividends reinvested · last 1yPYXS +52.4% (+52.4%/yr)RNA -46.0% (-46.0%/yr)PYXS compounded faster over this window
PYXS RNA
PYXS vs RNA: by the numbers
- •RNA is the larger company ($136M vs $130M market cap).
- •Both run net losses; RNA's is the smaller (-396.52% vs -803.83% net margin).
Metrics side by side
Valuation
| Metric | PYXS | RNA |
|---|---|---|
| P/S ratio | 11.78 | 5.81 |
| P/B ratio | 11.37 | 0.64 |
Profitability
| Metric | PYXS | RNA |
|---|---|---|
| Gross margin | 82.77% | 97.90% |
| Operating margin | -609.18% | -410.23% |
| Net margin | -803.83% | -396.52% |
| ROE | -775.59% | -43.42% |
| ROIC | -314.66% | -38.45% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.